TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36411567

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (risperidone 2‐6 mg/d, olanzapine 5‐20 mg/d, quetiapine 400‐750 mg/d, aripiprazole 10‐30 mg/d, ziprasidone 80‐160 mg/d)
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Typical antipsychotics (perphenazine 20‐60 mg/d, haloperidol 6‐20 mg/d)
Number of subjects: 3010
Study: 34981693

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 40
Study: 33279854

Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg at day 1 of each cycle) and Tremelimumab (75 mg at day 1 for 4 cycles) - Arm A
Number of subjects: 20

Group type: COMPARATOR
Intervention: Durvalumab, Tremelimumab with Paclitaxel (80 mg/m2 at D1, D8, D15) - Arm B
Number of subjects: 20
Study: 32609960

Group type: EXPERIMENTAL
Intervention: INP105 5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: INP105 10 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: INP105 15 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: OLZ IM 5 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: OLZ IM 10 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: OLZ ODT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33170731

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 32066609

Group type: EXPERIMENTAL
Intervention: Patient Safety Problems (PSPs)
Number of subjects: 10037

Group type: EXPERIMENTAL
Intervention: Anamnesis/diagnostic procedures
Number of subjects: 10037

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 10037

Group type: EXPERIMENTAL
Intervention: General practitioners
Number of subjects: 10037

Group type: EXPERIMENTAL
Intervention: Permanent harm
Number of subjects: 10037

Group type: EXPERIMENTAL
Intervention: Additional treatment
Number of subjects: 10037

Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 10037
Study: 35797268

Group type: EXPERIMENTAL
Intervention: Unity-framed messages
Number of subjects: 136

Group type: COMPARATOR
Intervention: Dualism-framed messages
Number of subjects: 136
Study: 32588228

Group type: EXPERIMENTAL
Intervention: Tech Connect
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard community-based mental health care (control)
Number of subjects: 20
Study: 33533654

Group type: EXPERIMENTAL
Intervention: Intralesional MMR vaccine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intralesional Candida antigen
Number of subjects: 68
Study: 33180097

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg, 3 times daily for 15 days
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo, 3 times daily for 15 days
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 35466645

Group type: COMPARATOR
Intervention: Intravitreal Bevacizumab (IVB) alone
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab (IVB) + Focal Macular Photocoagulation (FMP)
Number of subjects: 260
Study: 32116248

Group type: EXPERIMENTAL
Intervention: Learning Therapy (LT), a combination of cognitive training and stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33576434

Group type: EXPERIMENTAL
Intervention: Person-centred intervention with digital platform support for 6 months
Number of subjects: 139

Group type: COMPARATOR
Intervention: Active control group with one follow-up phone call
Number of subjects: 139
Study: 32397926

Group type: COMPARATOR
Intervention: eTICI 2B
Number of subjects: 2807

Group type: EXPERIMENTAL
Intervention: eTICI 3
Number of subjects: 2807

Group type: EXPERIMENTAL
Intervention: eTICI 2C
Number of subjects: 2807
Study: 35451656

Group type: EXPERIMENTAL
Intervention: Toothbrushing supplemented by dental floss (TB + DF)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Toothbrushing (TB) alone
Number of subjects: 75
Study: 34159432

Group type: EXPERIMENTAL
Intervention: E-cigarette with 10% 13C-labeled propylene glycol and glycerol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cigarettes spiked with the described e-liquid
Number of subjects: 25
Study: 36451915

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 36
Study: 32572483

Group type: EXPERIMENTAL
Intervention: Alternative-ASDAS using BASDAI total score as PGA replacement
Number of subjects: 2085

Group type: COMPARATOR
Intervention: Original-ASDAS
Number of subjects: 2085
Study: 32506275

Group type: EXPERIMENTAL
Intervention: Preoperative meloxicam 15 mg at 24 h pre-operation, 7.5 mg at 4 h, 24 h, 48 h and 72 h post-operation
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Preoperative meloxicam
Number of subjects: 132

Group type: COMPARATOR
Intervention: Postoperative meloxicam 15 mg at 4 h post-operation, then 7.5 mg at 24 h, 48 h and 72 h post-operation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Postoperative meloxicam
Number of subjects: 132
Study: 33068770

Group type: EXPERIMENTAL
Intervention: Simulation session in addition to companionship-training (Intervention group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Companionship training only (Control group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups (Intervention and Control)
Number of subjects: 56
Study: 33285743

Group type: COMPARATOR
Intervention: Afatinib monotherapy (20-40 mg)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Afatinib plus HAD-B1 combination therapy (0.972 g/day for 48 weeks)
Number of subjects: 178
Study: 35691037

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Minimal acupuncture (MA)
Number of subjects: 21
Study: 34514815

Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 10533
Study: 35859388

Group type: EXPERIMENTAL
Intervention: Yoga-based lifestyle intervention (YBLI)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Non-yoga group
Number of subjects: 140
Study: 33336870

Group type: EXPERIMENTAL
Intervention: Antihyperglycaemic trials
Number of subjects: 1059
Study: 32544356

Group type: EXPERIMENTAL
Intervention: 980 nm diode laser (Group 1, n=22)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 980 nm diode laser probe placed in vestibule without radiation (Group 2, n=22)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No pre‐treatment (Group 3, n=12)
Number of subjects: 56
Study: 32894760

Group type: EXPERIMENTAL
Intervention: GATA3 polymorphism rs3824662
Number of subjects: 2597
Study: 34419030

Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Lecture-Based Learning (LBL)
Number of subjects: 115
Study: 32390113

Group type: EXPERIMENTAL
Intervention: Upfront autologous hematopoietic stem cell transplantation (ASCT) following rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Patients with DEL
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Patients with GCB subtype
Number of subjects: 67
Study: 34818873

Group type: EXPERIMENTAL
Intervention: BT200 (0.18-48 mg) subcutaneously
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: BT200 with concomitant desmopressin
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 112
Study: 34481910

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 162

Group type: COMPARATOR
Intervention: Teneligliptin
Number of subjects: 162
Study: 32811485

Group type: EXPERIMENTAL
Intervention: Virtual-Jaw (V-J) group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Jaw-Virtual (J-V) group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Virtual (V) group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Jaw (J) group
Number of subjects: 80
Study: 35238750

Group type: EXPERIMENTAL
Intervention: 8 mg pegloticase every 2 weeks (q2w)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 8 mg pegloticase every 4 weeks (q4w)
Number of subjects: 34
Study: 35293167

Group type: EXPERIMENTAL
Intervention: WALANT technique
Number of subjects: 48

Group type: COMPARATOR
Intervention: Epidural anesthesia with tourniquet
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: WALANT technique and CAMIR
Number of subjects: 48
Study: 34613954

Group type: EXPERIMENTAL
Intervention: Gluten challenges (0, 10, 50, 100, 500, and 1,000 mg) during study A
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Gluten challenge with 5 or 10 mg gluten during study B
Number of subjects: 37
Study: 32543258

Group type: EXPERIMENTAL
Intervention: Immediate maintenance pemetrexed therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Observation followed by pemetrexed at progression
Number of subjects: 105
Study: 35717354

Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 4628

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4628
Study: 33225965

Group type: EXPERIMENTAL
Intervention: Anakinra (300 mg daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 34859267

Group type: EXPERIMENTAL
Intervention: Distal Tibia Nail (DTN) with double locking
Number of subjects: 6

Group type: COMPARATOR
Intervention: Distal Tibia Nail (DTN) with triple locking
Number of subjects: 6
Study: 33626029

Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 32552685

Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 311
Study: 36459380

Group type: EXPERIMENTAL
Intervention: Enhanced patient navigation intervention
Number of subjects: 278
Study: 32439860

Group type: EXPERIMENTAL
Intervention: Probiotic containing Lactobacillus rhamnosus and Lactobacillus helveticus
Number of subjects: 816

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 816
Study: 32987227

Group type: EXPERIMENTAL
Intervention: FICare
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 185
Study: 34217236

Group type: EXPERIMENTAL
Intervention: RHD care at a tertiary hospital
Number of subjects: 100
Study: 32469398

Group type: EXPERIMENTAL
Intervention: Exercise plus lean red meat (Ex + Meat)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Exercise plus carbohydrate control (C + Ex)
Number of subjects: 154
Study: 36233636

Group type: EXPERIMENTAL
Intervention: Denneroll cervical traction orthotic + TENS therapy + hot packs
Number of subjects: 80

Group type: COMPARATOR
Intervention: TENS therapy + hot packs
Number of subjects: 80
Study: 34836149

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE; containing 500 mg epigallocatechin-3-gallate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study: 35468319

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 106
Study: 32828213

Group type: EXPERIMENTAL
Intervention: 3 Trauma Centers (TCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 Trauma Centers (TCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 Trauma Center (TC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average Transport Time (TT) with 3 TCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average Transport Time (TT) with 2 TCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average Transport Time (TT) with 1 TC
Number of subjects: 0
Study: 36371442

Group type: EXPERIMENTAL
Intervention: Mobile app (Health Manager) for 4 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Self-management education materials in a portable document format (Control)
Number of subjects: 33
Study: 32507389

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 241

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 241
Study: 33296798

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 32891272

Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: No aroma (control)
Number of subjects: 24
Study: 36152359

Group type: EXPERIMENTAL
Intervention: Schizophrenia group (n = 28)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Other mental illness group (n = 31)
Number of subjects: 86

Group type: COMPARATOR
Intervention: No mental illness group (n = 27)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: All groups (including schizophrenia and other mental illness)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 86
Study: 33929612

Group type: EXPERIMENTAL
Intervention: Cement-augmented odontoid screw (OG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Posterior-instrumented fusion (HG)
Number of subjects: 16
Study: 32402495

Group type: COMPARATOR
Intervention: Conventional microsuturing (Group I)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fibrin sealant reinforced microsuturing (Group II)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Couplers (Group III)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Staplers (Group IV)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Laser Assisted Vascular Anastomosis (LAVA) (Group V)
Number of subjects: 80
Study: 34117622

Group type: EXPERIMENTAL
Intervention: Early total enteral nutrition (80 mL/kg/d starting on day 1, advanced by 20 mL/kg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (30 mL/kg/d starting on day 1, advanced by 20 mL/kg/d)
Number of subjects: 60
Study: 34948514

Group type: EXPERIMENTAL
Intervention: Individualized Stroop task (MF condition)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Watching a documentary (control condition)
Number of subjects: 11
Study: 34550306

Group type: EXPERIMENTAL
Intervention: Addition strategy (increased portions of low-energy-dense vegetables and fruits by 50%)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Substitution strategy (increased portions of vegetables and fruits by 50% and reduced portions of other foods by equivalent weight)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Addition strategy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Substitution strategy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (typical portions for all food groups)
Number of subjects: 53
Study: 34526434

Group type: COMPARATOR
Intervention: ARC‐HBR criteria group 0 (0 major with ≤ 1 minor, N=6,792)
Number of subjects: 12093

Group type: EXPERIMENTAL
Intervention: ARC‐HBR criteria group 1 (1 major with 0 minor, N=1,705)
Number of subjects: 12093

Group type: EXPERIMENTAL
Intervention: ARC‐HBR criteria group 2 (0 major with ≥ 2 minors, N=790)
Number of subjects: 12093

Group type: EXPERIMENTAL
Intervention: ARC‐HBR criteria group 3 (1 major with ≥ 1 minor, N=1,709)
Number of subjects: 12093

Group type: EXPERIMENTAL
Intervention: ARC‐HBR criteria group 4 (2 majors with ≥ 0 minors, N=861)
Number of subjects: 12093

Group type: EXPERIMENTAL
Intervention: ARC‐HBR criteria group 5 (≥ 3 majors with ≥ 0 minor, N=236)
Number of subjects: 12093

Group type: COMPARATOR
Intervention: Non-ARC‐HBR criteria group 0 (N=6,792)
Number of subjects: 12093
Study: 34016887

Group type: EXPERIMENTAL
Intervention: Biliopancreatic drainage
Number of subjects: 20

Group type: COMPARATOR
Intervention: Biliary drainage
Number of subjects: 20
Study: 32173035

Group type: EXPERIMENTAL
Intervention: Congenitally blind (CB) children
Number of subjects: 45

Group type: COMPARATOR
Intervention: Eyes closed (EC) group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Eyes open (EO) group
Number of subjects: 45
Study: 35871814

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg per day
Number of subjects: 727

Group type: COMPARATOR
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 727
Study: 33617144

Group type: EXPERIMENTAL
Intervention: Alpine treeline ecotones (ATEs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Other forest ecotones (OFEs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Forests below ATEs
Number of subjects: 10
Study: 32150215

Group type: EXPERIMENTAL
Intervention: 6-month structured physical activity with or without a protein and vitamin D nutritional supplement
Number of subjects: 99
Study: 35075385

Group type: EXPERIMENTAL
Intervention: Huaiqihuang granules combined with comprehensive nursing
Number of subjects: 104

Group type: COMPARATOR
Intervention: Glucocorticoid (Control)
Number of subjects: 104
Study: 34246888

Group type: EXPERIMENTAL
Intervention: Palmitoleic acid (genetically predicted levels)
Number of subjects: 14361

Group type: EXPERIMENTAL
Intervention: Oleic acid (genetically predicted levels)
Number of subjects: 14361

Group type: COMPARATOR
Intervention: Genetic predisposition to MUFAs
Number of subjects: 14361
Study: 35619221

Group type: EXPERIMENTAL
Intervention: Melatonin treatment (10 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 17
Study: 34424558

Group type: EXPERIMENTAL
Intervention: Treatment shampoo and leave‐on treatment containing functional antioxidants and barrier‐enhancing agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo chassis shampoo control
Number of subjects: 0
Study: 32334176

Group type: EXPERIMENTAL
Intervention: Clinically indicated replacement group (removal only at end of therapy or in presence of complications)
Number of subjects: 1319

Group type: COMPARATOR
Intervention: Routine replacement group (catheters replaced every 96 hours unless clinical reasons required earlier replacement)
Number of subjects: 1319
Study: 34265165

Group type: EXPERIMENTAL
Intervention: Coffee pulp drink (CPD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Coffee pulp serum (CPS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo serum
Number of subjects: 80
Study: 33421538

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation with multimodal exercise program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups (EG and CG)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Experimental group (EG)
Number of subjects: 46
Study: 35035241

Group type: EXPERIMENTAL
Intervention: Asian ginseng and American ginseng
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Publication date and sample size
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Rigorous RCTs designed for ginseng
Number of subjects: 91
Study: 32590482

Group type: EXPERIMENTAL
Intervention: Bromfenac ophthalmic solution 0.09% prescribed 3 times a day for 1 month
Number of subjects: 450

Group type: COMPARATOR
Intervention: Prednisolone acetate 1% eye suspension prescribed 4 times a day for 1 month
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Prednisolone acetate 1% prescribed 4 times a day for 2 weeks and bromfenac 2 times a day for 1 month
Number of subjects: 450
Study: 35418437

Group type: EXPERIMENTAL
Intervention: MLC901 (NeuroAiD II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36281150

Group type: EXPERIMENTAL
Intervention: Rehabilitation (30 minutes)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MLD plus Rehabilitation (30 minutes MLD + 30 minutes rehabilitation)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MLD plus Rehabilitation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 39
Study: 33557898

Group type: EXPERIMENTAL
Intervention: Shi-style cervical manipulation therapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: NSAIDs (traditional analgesic drug)
Number of subjects: 240
Study: 34938867

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 199

Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 199
Study: 34612617

Group type: EXPERIMENTAL
Intervention: 8.4% sodium bicarbonate
Number of subjects: 90

Group type: COMPARATOR
Intervention: 20% mannitol
Number of subjects: 90

Group type: COMPARATOR
Intervention: 3% hypertonic saline
Number of subjects: 90
Study: 32464957

Group type: EXPERIMENTAL
Intervention: CLAD patients (M30, MUC1, MUC16)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RAS/mixed phenotype patients (M30)
Number of subjects: 45

Group type: COMPARATOR
Intervention: CLAD-free controls
Number of subjects: 45
Study: 32567869

Group type: EXPERIMENTAL
Intervention: Transgender affirmative psychotherapy (TA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Building Awareness of Minority Stressors + Transgender Affirmative psychotherapy
Number of subjects: 20
Study: 32246685

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 15
Study: 33978329

Group type: EXPERIMENTAL
Intervention: Modifiable risk factors
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Nonmodifiable risk factors
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Both modifiable and nonmodifiable risk factors
Number of subjects: 380

Group type: COMPARATOR
Intervention: Overall risk factors presence
Number of subjects: 380
Study: 33331082

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg IV every 4 weeks; 6 doses)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 30
Study: 36443789

Group type: EXPERIMENTAL
Intervention: Social risk screening and assessment of desire for assistance using the Accountable Health Communities instrument.
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Desire for assistance assessment.
Number of subjects: 228
Study: 35833970

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) underwent a 1-year lifestyle intervention with 4 months of active weight loss (WL) followed by 8 months of WL maintenance.
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) after weight loss (WL)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) with higher energy conservation
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 94
Study: 37749703

Group type: EXPERIMENTAL
Intervention: Fortified milk (1500 IU vitamin D3)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Fortified yogurt (1500 IU vitamin D3)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Plain milk (Control)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Plain yogurt (Control)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Fortified products (milk and yogurt)
Number of subjects: 289